CLYM Q2 2025 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena

CLYMClimb Bio, Inc.

$522M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$38,000

Operating Income

-$11M

Net Income

-$9M

EPS (Diluted)

$-0.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$192M

Total Liabilities

$7M

Stockholders' Equity

$186M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$38,000	$0	—
Operating Income	-$11M	-$56M	+81.1%
Net Income	-$9M	-$55M	+84.2%